Page 16 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 11 ฉบับที่ 1

10 «“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë 11 ©∫—∫∑’Ë 1 ¡°√“§¡-‡¡…“¬π 2556

tetramethylluteolin ¡’ƒ∑∏‘Ï·√ß„π°“√¬—∫¬—Èß°“√ ¡’ƒ∑∏‘Ï°√–μÿâπ°“√ – ¡ doxorubicin Ÿß ÿ¥ ·≈–
43
√â“߉πμ√‘°ÕÕ°‰´¥å„π‡´≈≈å RAW264.7 ‡¡◊ËÕ∂Ÿ° ™à«¬≈¥°“√¥◊ÈÕ¬“π’ȉ¥â
°√–μÿâπ¥â«¬ LPS ·≈–¡’ƒ∑∏‘Ï·√ߪ“π°≈“ß„π°“√ O à«π°“√»÷°…“º≈μàÕ°“√∑”ß“π¢Õß P-glyco-
¬—∫¬—Èß°“√ √â“ß TNFα “√∑—Èß “¡™π‘¥¬—ß¡’ƒ∑∏‘Ï·√ß protein „π‡´≈≈å¡–‡√Á߇¬◊ËÕ∫ÿ‰μ LLC-GA5-COL150

„π°“√¬—∫¬—Èß°“√· ¥ßÕÕ°¢Õß iNOS mRNA ·≈– ∑’Ë¥◊ÈÕμàÕ¬“μâ“π¡–‡√ÁßÀ≈“¬™π‘¥ (‡ªìπ porcine kid-
iNOS protein ‚¥¬¡’§«“¡ —¡æ—π∏å°—∫¢π“¥§«“¡ ney epithelial cell line LLC-PK1 ∑’Ë∂Ÿ° trans-
38
‡¢â¡¢âπ∑’Ë„Àâ fected ¥â«¬ human MDR1 cDNA) æ∫«à“ “√
6. æ‘…μàÕ‡´≈≈å¡–‡√Áß (cytotoxicity) ·≈– °—¥¥â«¬‡Õ∑“πÕ≈¡’ƒ∑∏‘Ï¥’°«à“ “√ °—¥¥â«¬πÈ”„π
ƒ∑∏‘ϙ૬≈¥°“√¥◊ÈÕ¬“ chemotherapy °“√‡æ‘Ë¡°“√ – ¡¢Õß “√¬âÕ¡ rhodamine 123

¡’√“¬ß“π°“√»÷°…“„π‡´≈≈å¡–‡√Á߇擖‡≈’È¬ß ·≈–¬“¡–‡√Áß daunorubicin „π‡´≈≈å¡–‡√Áßπ’È ·≈–
æ∫«à“ “√ °—¥°√–™“¬¥”¥â«¬‡Õ∑“πÕ≈ À√◊Õ “√°≈ÿà¡ “√ 3,5,7,3û,4û-pentamethoxyflavone ¡’ƒ∑∏‘Ï
methoxyflavones ‡ªìπæ‘…μàÕ‡´≈≈å¡–‡√ÁßÀ≈“¬™π‘¥ Ÿß ÿ¥„π°“√‡æ‘Ë¡°“√ – ¡ rhodamine 123 ·≈–

·≈–/À√◊Õ ∑”„À⇰‘¥ apoptosis μàÕ‡´≈≈å¡–‡√Áß ‡™àπ daunorubicin ‚¥¬°“√¬—∫¬—Èß°“√∑”ß“π¢Õß P-gly-
‡´≈≈å¡–‡√Áß∑àÕπÈ”¥’ [Human cholangiocarcinoma coprotein function ∑”„ÀâÕ“®¡’»—°¬¿“æ„π°“√
39
cell lines (HuCCA-1 & RMCCA-1 cells)] , ‡´≈≈å ·°âªí≠À“‡´≈≈å¡–‡√Áߥ◊ÈÕ¬“À≈“¬™π‘¥∑’Ë¡’°≈‰°ºà“π P-
40
¡–‡√Á߇¬◊ËÕ∫ÿ™àÕߪ“° (KB cell line) , ‡´≈≈å¡–‡√Áß glycoprotein ·≈–™à«¬‡æ‘Ë¡ bioavailability ¢Õ߬“
44
‡¡Á¥‡≈◊Õ¥¢“«™π‘¥ myeloblastic leukemia (HL- ¡–‡√Áß
41
60 cells) ·≈–‡´≈≈å¡–‡√Á߇¡Á¥‡≈◊Õ¥¢“«™π‘¥ Hu- 7. ƒ∑∏‘Ïμâ“π°“√·æâ (anti-allergy activity)
42
man leukemic U937 cell line “√ °—¥°√–™“¬¥”¥â«¬‡Õ∑“πÕ≈· ¥ßƒ∑∏‘Ï
πÕ°®“°π’È ¡’√“¬ß“π°“√«‘®—¬®“°¡À“«‘∑¬“≈—¬ μâ“π°“√·æâ ‚¥¬¬—∫¬—Èß°“√À≈—Ëß β-hexosaminidase

Œ‘‚√™‘¡“ 2 √“¬ß“π ∑’Ë»÷°…“ƒ∑∏‘Ï¢Õß “√ °—¥ ®“°°“√¬—∫¬—Èß°“√·μ°¢Õß·°√πŸ≈ (degranulation)
°√–™“¬¥”¥â«¬πÈ”·≈–¥â«¬‡Õ∑“πÕ≈ ·≈– “√°≈ÿà¡ ®“°‡´≈≈å RBL-2H3 (´÷Ë߇ªìπ‚¡‡¥≈¢Õß mast cell)
‡ø≈‚«πÕ¬¥å®“°°√–™“¬¥”„π°“√≈¥°“√¥◊ÈÕ¬“¢Õß ∑’Ë∂Ÿ°°√–μÿâπ¥â«¬ allergen ‚¥¬¡’§à“ IC = 10.9
50
‡´≈≈å¡–‡√Áß ‰¥â·°à ¡§°./¡≈. “√ ”§—≠∑’Ë¡’ƒ∑∏‘Ïμâ“π°“√·æâ·√ß∑’Ë ÿ¥ §◊Õ
O °“√»÷°…“º≈μàÕ°“√∑”ß“π¢Õß‚ª√μ’π∑’Ë 5-hydroxy-3,7,3',4'-tetramethoxyflavone ¡’§à“

‡°’ˬ«¢âÕß°—∫°“√¥◊ÈÕ¬“¶à“‡´≈≈å¡–‡√ÁßÀ≈“¬™π‘¥ IC = 8.0 μg/ml ‚¥¬ÕÕ°ƒ∑∏‘Ϭ—∫¬—Èß°“√‡§≈◊ËÕπ¢Õß
50
46
(multidrug resistance-associated proteins) ·§≈‡´’¬¡‡¢â“‡´≈≈å
„π‡´≈≈å¡–‡√Áߪե™π‘¥ A549 æ∫«à“ “√ °—¥ 8. ƒ∑∏‘Ïμâ“π‡™◊ÈÕ®ÿ≈‘π∑√’¬å

°√–™“¬¥”¥â«¬‡Õ∑“πÕ≈¡’ƒ∑∏‘Ï¥’°«à“ “√ °—¥¥â«¬ “√ 5,7,4û-trimethoxyflavone ·≈– 5,7,3û,4û
πÈ”„π°“√‡æ‘Ë¡°“√ – ¡¢Õß calcein ( ’¬âÕ¡‡√◊Õß -tetramethoxyflavone · ¥ßƒ∑∏‘Ïμâ“π‡™◊ÈÕ¡“‡≈‡√’¬

· ßø≈ŸÕÕ‡√ ‡´π å„™â¬âÕ¡‡´≈≈å¡’™’«‘μ) ·≈–¬“¡–‡√Áß Plasmodium falciparum à«π “√ 3,5,7,4û-
doxorubicin „π‡´≈≈åπ’È ·≈– 5,7-dimethoxyflvone tetramethoxyflavone ·≈– 5,7,4û-trimetho-